Company Overview

LeMaitre Vascular, Inc. is a U.S.-based medical device company focused on the development, manufacture, and marketing of products used primarily in the treatment of peripheral vascular disease and related conditions. The company operates within the broader vascular surgery and cardiovascular medical technology industries, serving hospitals, vascular surgeons, cardiovascular surgeons, and interventional specialists. Its product portfolio includes vascular grafts, biologic patches, carotid shunts, valvulotomes, embolectomy catheters, surgical sealants, and devices used in open vascular surgery procedures. Revenue is primarily generated through direct product sales to healthcare providers and distributors across multiple international markets.

LeMaitre Vascular has positioned itself as a specialized provider in niche vascular surgery markets that are often underserved by larger diversified medical device manufacturers. The company emphasizes surgeon-focused product development, targeted acquisitions, and direct sales infrastructure. Founded in 1983 by vascular surgeon Dr. George LeMaitre, the company initially concentrated on devices supporting vascular surgical procedures and later expanded through acquisitions and internal product innovation. Over time, it evolved into a global vascular device company with a portfolio spanning biologic implants, vascular access products, and surgical tools.

Business Operations

LeMaitre Vascular organizes its operations around the sale of vascular surgery products rather than through large diversified reporting segments. Key revenue-generating product categories include biologic vascular patches, vascular grafts, carotid shunts, anastomotic clips, valvulotomes, embolectomy and thrombectomy catheters, and surgical adhesives. The company manufactures and distributes products through a combination of internal production facilities and third-party suppliers. Important product and business lines include Artegraft, XenoSure, AlboGraft, RestoreFlow, and AnastoClip technologies, many of which were expanded through acquisitions.

The company maintains direct sales operations in the United States, Europe, Canada, and parts of the Asia-Pacific region, supplemented by distributor networks in additional international markets. LeMaitre Vascular controls manufacturing and processing assets related to biologic tissue products and vascular implants, including facilities involved in tissue processing and medical device production. Strategic acquisitions have historically played a significant role in expanding the company’s intellectual property, surgeon relationships, and specialized vascular product portfolio. The company has also maintained relationships with hospitals, academic medical centers, and surgical networks that support product adoption and clinical utilization.

Strategic Position & Investments

LeMaitre Vascular’s strategy has centered on expanding its leadership in niche vascular surgery markets through targeted acquisitions, surgeon-oriented product development, and geographic expansion. The company has consistently invested in biologic implant technologies and products used in open vascular procedures, areas where competition from larger cardiovascular device firms is less concentrated. Acquisitions such as Artegraft, CardioCel, Admedus’ vascular patch business, and Applied Medical’s vascular closure products contributed to portfolio diversification and recurring procedural demand.

The company has also invested in biologic materials, bovine and porcine tissue technologies, and products supporting vascular reconstruction and repair. Its acquisition strategy generally focuses on products with established clinical usage and relatively defensible market positions within vascular surgery. LeMaitre Vascular’s emphasis on specialized sales teams and niche procedural expertise has been identified in public filings and investor communications as a strategic differentiator. The company continues to evaluate opportunities in biologic vascular implants, surgical device innovation, and international market penetration.

Geographic Footprint

LeMaitre Vascular is headquartered in Burlington, Massachusetts, and maintains operations across North America, Europe, and the Asia-Pacific region. The company generates revenue from both domestic and international markets, with a meaningful portion of sales originating outside the United States. International operations include direct sales offices in countries such as Germany, France, United Kingdom, Italy, Spain, Japan, and Canada, along with distributor-supported markets in additional regions.

The company’s products are marketed in more than 100 countries through a combination of direct and indirect channels. Its international footprint supports access to vascular surgery markets across developed healthcare systems, particularly in Western Europe and North America. Manufacturing, tissue processing, and distribution capabilities are primarily concentrated in the United States and Europe, supporting global product distribution and regulatory compliance across multiple jurisdictions.

Leadership & Governance

LeMaitre Vascular was founded by vascular surgeon Dr. George LeMaitre, whose clinical background influenced the company’s long-term focus on surgeon-centric product development and niche vascular procedures. The company operates under a leadership philosophy emphasizing disciplined acquisitions, specialization in peripheral vascular surgery, and long-term operational growth supported by recurring procedural demand. Public company disclosures and investor materials indicate a continued focus on profitability, targeted innovation, and international expansion.

Key executives include:

• George W. LeMaitre – Chairman of the Board
• George W. LeMaitre – Founder
• David B. Roberts – President and Chief Executive Officer
• Joseph P. Vitale – Chief Financial Officer
• Christopher M. Boucher – Senior Vice President, Global Sales
• Michael G. Lawless – Senior Vice President, Operations
• Bernard J. O’Brien – Senior Vice President, Human Resources

The company is publicly traded on the NASDAQ under the ticker LMAT and provides governance disclosures through annual reports, proxy filings, and other SEC filings, including Form 10-K and DEF 14A documents. Publicly available filings indicate a governance structure combining executive leadership continuity with board oversight focused on operational execution and shareholder returns.